Compare AKR & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKR | IBRX |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 1993 | N/A |
| Metric | AKR | IBRX |
|---|---|---|
| Price | $21.09 | $5.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $22.00 | $11.50 |
| AVG Volume (30 Days) | 1.5M | ★ 18.5M |
| Earning Date | 02-10-2026 | 03-02-2026 |
| Dividend Yield | ★ 3.82% | N/A |
| EPS Growth | ★ 18.54 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $389,489,000.00 | $82,555,000.00 |
| Revenue This Year | N/A | $667.58 |
| Revenue Next Year | $16.18 | $92.92 |
| P/E Ratio | $169.77 | ★ N/A |
| Revenue Growth | 6.01 | ★ 1025.95 |
| 52 Week Low | $16.98 | $1.83 |
| 52 Week High | $24.95 | $4.27 |
| Indicator | AKR | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.97 | 92.86 |
| Support Level | $20.67 | $1.95 |
| Resistance Level | $21.20 | $2.29 |
| Average True Range (ATR) | 0.45 | 0.28 |
| MACD | 0.00 | 0.30 |
| Stochastic Oscillator | 84.80 | 98.48 |
Acadia Realty Trust is a real estate investment trust that specializes in the operation, management, leasing, renovation, and acquisition of shopping centers and mixed-use properties with retail components. The company operates through three segments: Core Portfolio segment consists primarily of high-quality retail properties located primarily in high-barrier-to-entry, densely-populated metropolitan areas with a long-term investment horizon; Investment Management segment holds primarily retail real estate in which the company co-invests with high-quality institutional investors; and Structured Financing segment consists of earnings and expenses related to notes and mortgages receivable Fees earned by the company as the general partner or managing member through Investment Management.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.